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1. Introduction
These guidelines represent an update of those published in
1996 and are intended for physicians who are involved in
the preoperative, operative, and postoperative care of
patients undergoing noncardiac surgery. They provide a
framework for considering cardiac risk of noncardiac
surgery in a variety of patient and surgical situations. The
overriding theme of these guidelines is that preoperative
intervention is rarely necessary simply to lower the risk of
surgery unless such intervention is indicated irrespective
of the preoperative context. The purpose of preoperative
evaluation is not simply to give medical clearance but
rather to perform an evaluation of the patient’s current
medical status; make recommendations concerning the
evaluation, management, and risk of cardiac problems over
the entire perioperative period; and provide a clinical risk
profile that the patient, primary physician, anesthesiolo-
gist, and surgeon can use in making treatment decisions
that may influence short- and long-term cardiac outcomes.
The goal of the consultation is to identify the most
appropriate testing and treatment strategies to optimize
care of the patient, provide assessment of both short- and
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long-term cardiac risk, and avoid unnecessary testing in
this era of cost containment.
A. Development of Guidelines
These guidelines are based on an update of a Medline,
EMBASE, Cochrane library, and Best Evidence search of the
English literature from 1995 through 2000, a review of
selected journals, and the expert opinions of 12 committee
members representing various disciplines of cardiovascular
care, including general cardiology, interventional cardiology,
noninvasive testing, vascular medicine, vascular surgery,
anesthesiology, and arrhythmia management. As a result of
these searches, more than 400 relevant new articles were
identified. In addition, draft guidelines were submitted for
critical review and amendment to the executive officers
representing the American College of Cardiology (ACC) and
the American Heart Association (AHA).
A large proportion of the data used to develop these
guidelines are based on observational or retrospective studies
or knowledge of management of cardiovascular disorders in
the nonoperative setting. Although the collective body of
knowledge about the identification of high- and low-risk
patients by perioperative clinical and noninvasive evaluation
is substantial, the number of prospective or randomized
studies that have been performed to establish the value of
different treatments on perioperative outcomes is small. The
ACC/AHA classifications of evidence used in this report to
summarize the indication for a particular therapy or treatment
are as follows:
Class I: Conditions for which there is evidence and/or
general agreement that a given
procedure/therapy is useful and effective.
Class II: Conditions for which there is conflicting
evidence and/or a divergence of opinion
about the usefulness/efficacy of performing
the procedure/therapy.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well
established by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/therapy
is not useful/effective and in some cases may
be harmful.
Two versions of the full-text guidelines are available on the
World Wide Web sites of both the American College of
Cardiology (www.acc.org) and the American Heart Associa-
tion (www.americanheart.org); one version highlights the
updated material (deleted text in strikeout and new text in
red), and the other fully incorporates the changes. This
document was approved for publication by the governing
bodies of the ACC and the AHA, will be reviewed annually
by the Task Force, and will be considered current unless the
Task Force revises or withdraws them from distribution.
B. General Approach
The preoperative cardiac evaluation must be carefully tai-
lored to the circumstances that have prompted the consulta-
tion and to the nature of the surgical illness (e.g., acute
surgical emergency) as opposed to urgent or elective cases.
Successful perioperative evaluation and treatment of cardiac
patients undergoing noncardiac surgery requires careful
teamwork and communication between the patient, primary
care physician, anesthesiologist, consultant, and surgeon. In
general, indications for further cardiac testing and treatments
are the same as those in the nonoperative setting, but their
timing is dependent on such factors as the urgency of
noncardiac surgery, the patient’s risk factors, and specific
surgical considerations. Coronary revascularization before
noncardiac surgery to enable the patient to “get through” the
noncardiac procedure is appropriate only for a small subset of
patients at very high risk. Preoperative testing should be
limited to circumstances in which the results will affect
patient treatment and outcomes. A conservative approach to
the use of expensive tests and treatments is recommended.
C. Preoperative Clinical Evaluation
The initial history, physical examination, and electrocardio-
gram (ECG) assessment should focus on identification of
potentially serious cardiac disorders, including coronary ar-
tery disease (CAD) [e.g., prior myocardial infarction (MI)
and angina pectoris], heart failure (HF), symptomatic arrhyth-
mias, presence of pacemaker or implantable cardioverter
defibrillator (ICD), or a history of orthostatic intolerance.1
The presence of anemia may also place a patient at higher
perioperative risk.2–4
In addition to identifying the presence of pre-existing
manifested heart disease, it is essential to define disease
severity, stability, and prior treatment. Other factors that help
determine cardiac risk include functional capacity, age, co-
morbid conditions (e.g., diabetes mellitus, peripheral vascular
disease, renal dysfunction, and chronic pulmonary disease),
and type of surgery (vascular procedures and prolonged,
complicated thoracic, abdominal, and head and neck proce-
dures are considered higher risk).
Numerous risk indices have been developed over the past
25 years on the basis of multivariate analyses.5–14 In addition
to the presence of CAD and HF, a history of cerebrovascular
disease, preoperative elevated creatinine greater than 2 mg
per deciliter, insulin treatment for diabetes mellitus, and
high-risk surgery have all been associated with increased
perioperative cardiac morbidity. Despite these risk indices,
there was consensus among the committee members to place
clinical risk factors into 3 categories of predictors (see
Section II-A).
II. Further Preoperative Testing to Assess
Coronary Risk
Which patients are most likely to benefit from preoperative
coronary assessment and treatment? The lack of adequately
controlled or randomized clinical trials to define the optimal
evaluation strategy led to the proposed algorithm based on
collected observational data and expert opinion (see Fig. 1).
Since publication of the guidelines in 1996, several studies
have suggested that this stepwise approach to the assessment
of CAD is both efficacious and cost-effective.
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A stepwise bayesian strategy that relies on assessment of
clinical markers, prior coronary evaluation and treatment,
functional capacity, and surgery-specific risk is outlined in
Figure 1. A framework for determining which patients are
candidates for cardiac testing is presented in algorithmic
form. Successful use of the algorithm requires an appreciation
of the different levels of risk attributable to certain clinical
circumstances, levels of functional capacity, and types of
surgery. These are defined below, after which the algorithm is
reviewed step by step.
A. Clinical Markers
The major clinical predictors (Table 1) of increased periop-
erative cardiovascular risk are a recent unstable coronary
syndrome such as an acute MI (documented MI less than 7
days previously), recent MI (more than 7 days but less than 1
month before surgery), unstable or severe angina, evidence of
a large ischemic burden by clinical symptoms or noninvasive
testing, decompensated HF, significant arrhythmias (high-
grade atrioventricular block, symptomatic arrhythmias in the
presence of underlying heart disease, or supraventricular
arrhythmias with uncontrolled ventricular rate), and severe
valvular disease.
Intermediate predictors of increased risk are mild angina
pectoris, a more remote prior MI (more than 1 month before
planned surgery), compensated HF, preoperative creatinine
greater than or equal to 2.0 mg per deciliter, and diabetes
mellitus. Minor predictors of risk are advanced age, abnormal
ECG, rhythm other than sinus, low functional capacity,
history of stroke, and uncontrolled systemic hypertension.
A history of MI or abnormal Q waves by ECG is listed as
an intermediate predictor, whereas an acute MI (defined as at
least 1 documented MI less than or equal to 7 days before the
examination) or recent MI (more than 7 days but less than or
equal to 1 month before the examination) with evidence of
important ischemic risk by clinical symptoms or noninvasive
study is a major predictor. This definition reflects the con-
sensus of the ACC Cardiovascular Database Committee. In
this way, the separation of MI into the traditional 3- and
6-month intervals has been avoided.6,15 Current management
of MI provides for risk stratification during convalescence.16
If a recent stress test does not indicate residual myocardium
at risk, the likelihood of reinfarction after noncardiac surgery
is low. Although there are no adequate clinical trials on which
to base firm recommendations, it appears reasonable to wait
4 to 6 weeks after MI to perform elective surgery.
B. Functional Capacity
Functional capacity can be expressed in metabolic equivalent
(MET) levels (Table 2). Multiples of the baseline MET value
can be used to express aerobic demands for specific activities.
Perioperative cardiac and long-term risks are increased in
patients unable to meet a 4-MET demand during most normal
daily activities.17–19 The Duke Activity Status Index and other
activity scales provide the clinician with a set of questions to
determine a patient’s functional capacity.20–22 Energy expen-
ditures for activities such as eating, dressing, walking around
the house, and dishwashing range from 1 to 4 METs.
Climbing a flight of stairs, walking on level ground at 6.4 km
per hour, running a short distance, scrubbing floors, or
playing a game of golf represents 4 to 10 METs. Strenuous
sports such as swimming, singles tennis, and football often
exceed 10 METs.
C. Surgery-Specific Risk
Surgery-specific cardiac risk of noncardiac surgery is related
to 2 important factors: the type of surgery itself and the
degree of hemodynamic stress associated with the proce-
dures. The duration and intensity of coronary and myocardial
stressors can be helpful in estimating the likelihood of
perioperative cardiac events, particularly for emergency sur-
gery. Surgery-specific risk for noncardiac surgery can be
stratified as high, intermediate, and low (Table 3).23 High-risk
surgery includes major emergency surgery, particularly in the
elderly; aortic and other major vascular surgery; peripheral
vascular surgery; and anticipated prolonged procedures asso-
ciated with large fluid shifts and/or blood loss. Intermediate-
risk procedures include intraperitoneal and intrathoracic sur-
gery, carotid endarterectomy, head and neck surgery,
orthopedic surgery, and prostate surgery. Low-risk proce-
dures include endoscopic and superficial procedures, cataract
surgery, and breast surgery.
The following steps correspond to the algorithm presented
in Figure 1.
Step 1 What is the urgency of noncardiac surgery? Certain
emergencies do not allow time for preoperative
cardiac evaluation. Postoperative risk stratification
may be appropriate for some patients who have not
had such an assessment before.
Step 2 Has the patient undergone coronary revasculariza-
tion in the past 5 years? If so, and if clinical status
has remained stable without recurrent symptoms/
signs of ischemia, further cardiac testing is gener-
ally not necessary.24
Step 3 Has the patient had a coronary evaluation in the
past 2 years? If coronary risk was adequately
assessed and the findings were favorable, it is
usually not necessary to repeat testing unless the
patient has experienced a change or new symptoms
of coronary ischemia since the previous evaluation.
Step 4 Does the patient have an unstable coronary syn-
drome or a major clinical predictor of risk? When
elective noncardiac surgery is being considered, the
presence of unstable coronary disease, decompen-
sated HF, symptomatic arrhythmias, and/or severe
valvular heart disease usually leads to cancellation
or delay of surgery until the problem has been
identified and treated.
Step 5 Does the patient have intermediate clinical predic-
tors of risk? The presence or absence of prior MI by
history or ECG, angina pectoris, compensated or
prior HF, preoperative creatinine greater than or
equal to 2 mg per deciliter, and/or diabetes mellitus
helps to further stratify clinical risk for periopera-
tive coronary events. Consideration of functional
capacity and level of surgery-specific risk allows a
rational approach to identify patients most likely to
benefit from further noninvasive testing.
Step 6 Patients without major but with intermediate pre-
dictors of clinical risk and moderate or excellent
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Figure 1. Stepwise approach to preoperative cardiac assessment. Steps are discussed in text. *Subsequent care may include cancel-
lation or delay of surgery, coronary revascularization followed by noncardiac surgery, or intensified care.
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functional capacity can generally undergo
intermediate-risk surgery with little likelihood of
perioperative death or MI. Conversely, further
noninvasive testing is often considered for patients
with poor functional capacity or moderate func-
tional capacity but higher-risk surgery, especially
for patients with 2 or more intermediate predictors
of risk.
Step 7 Noncardiac surgery is generally safe for patients
with neither major nor intermediate predictors of
clinical risk and moderate or excellent functional
capacity (4 METs or greater). Additional testing
may be considered on an individual basis for
patients without clinical markers but with poor
functional capacity who are facing higher-risk op-
erations, particularly those with several minor clin-
ical predictors of risk who are scheduled to un-
dergo vascular surgery.
Step 8 The results of noninvasive testing can be used to
determine the need for additional preoperative
testing and treatment. In some patients with docu-
mented CAD, the risk of coronary intervention or
corrective cardiac surgery may approach or even
exceed the risk of the proposed noncardiac surgery.
This approach may be appropriate, however, if it
significantly improves the patient’s long-term
prognosis.
For some patients, a careful consideration of clinical,
surgery-specific, and functional status attributes leads to a
decision to proceed to coronary angiography.
III. Management of Specific Preoperative
Cardiovascular Conditions
A. Hypertension
Stage 3 hypertension (systolic blood pressure greater than or
equal to 180 mm Hg and diastolic blood pressure greater than
or equal to 110 mm Hg) should be controlled before surgery.
In many such instances, establishment of an effective regimen
can be achieved over several days to weeks of preoperative
outpatient treatment. If surgery is more urgent, rapid-acting
agents can be administered that allow effective control in a
matter of minutes or hours. Beta-blockers appear to be particu-
larly attractive agents. Continuation of preoperative antihyper-
tensive treatment through the perioperative period is critical.
B. Valvular Heart Disease
Indications for evaluation and treatment of valvular heart
disease are identical to those in the nonpreoperative setting.
Symptomatic stenotic lesions are associated with risk of
perioperative HF or shock and often require percutaneous
valvotomy or valve replacement before noncardiac surgery to
lower cardiac risk.6,25–27 Symptomatic regurgitant valve dis-
TABLE 1. Clinical Predictors of Increased Perioperative
Cardiovascular Risk (Myocardial Infarction, Heart
Failure, Death)
Major
Unstable coronary syndromes
• Acute or recent myocardial infarction with evidence of important ischemic
risk by clinical symptoms or noninvasive study
• Unstable or severe angina (Canadian class III or IV)
Decompensated heart failure
Significant arrhythmias
• High-grade atrioventricular block
• Symptomatic ventricular arrhythmias in the presence of underlying heart
disease
• Supraventricular arrhythmias with uncontrolled ventricular rate
Severe valvular disease
Intermediate
Mild angina pectoris (Canadian class I or II)
Previous myocardial infarction by history or pathological Q waves
Compensated or prior heart failure
Diabetes mellitus (particularly insulin-dependent)
Renal insufficiency
Minor
Advanced age
Abnormal ECG (left ventricular hypertrophy, left bundle-branch block, ST-T
abnormalities)
Rhythm other than sinus (e.g., atrial fibrillation)
Low functional capacity (e.g., inability to climb one flight of stairs with a
bag of groceries)
History of stroke
Uncontrolled systemic hypertension
ECG indicates electrocardiogram.
*The American College of Cardiology National Database Library defines
recent MI as greater than 7 days but less than or equal to 1 month (30 days);
acute MI is within 7 days.
†May include “stable” angina in patients who are unusually sedentary.
‡Campeau L. Grading of angina pectoris. Circulation. 1976;54:522–523.
TABLE 2. Estimated Energy Requirements for Various Activities
1 MET Can you take care of yourself? 4 METs Climb a flight of stairs or walk up a hill?
Eat, dress, or use the toilet? Walk on level ground at 4 mph or 6.4 km per h?
Walk indoors around the house? Run a short distance?
Walk a block or two on level
ground at 2 to 3 mph or 3.2 to
4.8 km per h?
Do heavy work around the house like scrubbing
floors or lifting or moving heavy furniture?
Participate in moderate recreational activities like
4 METs Do light work around the house
like dusting or washing dishes?
golf, bowling, dancing, doubles tennis, or
throwing a baseball or football?
Greater than
10 METs
Participate in strenuous sports like swimming,
singles tennis, football, basketball, or skiing?
MET indicates metabolic equivalent.
Adapted from the Duke Activity Status Index20 and AHA Exercise Standards.96
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ease is usually better tolerated perioperatively and may be
stabilized preoperatively with intensive medical therapy and
monitoring. Regurgitant valve disease can then be treated
definitively with valve repair or replacement after noncardiac
surgery. Medical therapy and monitoring are appropriate
when a delay of several weeks or months before noncardiac
surgery may have severe consequences. Exceptions may
include severe valvular regurgitation with reduced left ven-
tricular function, in which overall hemodynamic reserve is so
limited that destabilization during perioperative stresses is
likely.
C. Myocardial Disease
Dilated and hypertrophic cardiomyopathy are associated with an
increased incidence of perioperative HF.6,28,29 Management is aimed
at maximizing preoperative hemodynamic status and providing
intensive postoperative medical therapy and surveillance. An esti-
mate of hemodynamic reserve is useful for anticipating potential
complications from intraoperative or postoperative stress.
D. Arrhythmias and Conduction Abnormalities
The presence of an arrhythmia or cardiac conduction distur-
bance should provoke a careful evaluation for underlying
cardiopulmonary disease, drug toxicity, or metabolic abnor-
mality. Therapy should be initiated for symptomatic or
hemodynamically significant arrhythmias, first to reverse an
underlying cause and second to treat the arrhythmia. Indica-
tions for antiarrhythmic therapy and cardiac pacing are
identical to those in the nonoperative setting. Frequent
ventricular premature beats and/or asymptomatic nonsus-
tained ventricular tachycardia have not been associated with
an increased risk of nonfatal MI or cardiac death in the
perioperative period,30,31 and therefore, aggressive monitoring
or treatment in the perioperative period generally is not
necessary.
E. Implantable Pacemakers or ICDs
The type and extent of evaluation of a pacemaker or ICD
depend on the urgency of the surgery, whether a pacemaker
has unipolar or bipolar leads, whether electrocautery is
bipolar or unipolar, the distance between electrocautery and
pacemaker, and pacemaker dependency. ICD devices should
be programmed off immediately before surgery and then on
again postoperatively.
IV. Supplemental Preoperative Evaluation
Specific recommendations for supplemental preoperative
evaluation must be individualized to each patient and circum-
stance. The following may be appropriate in specific situations:
assessment of resting left ventricular function, exercise stress
testing, pharmacological stress testing, ambulatory ECG moni-
toring, and coronary angiography. In most ambulatory patients,
the test of choice is exercise ECG testing, which can both
provide an estimate of functional capacity and detect myocardial
ischemia through changes in the ECG and hemodynamic re-
sponse. In patients with important abnormalities on their resting
ECG (e.g., left bundle-branch block, left ventricular hypertrophy
with strain pattern, or digitalis effect), other techniques such as
exercise echocardiography or exercise myocardial perfusion
imaging should be considered. Recommendations regarding
individual testing modalities are given below.
A. Resting Left Ventricular Function
Resting left ventricular function has not been found to be a
consistent predictor of perioperative ischemic events.32–40
Recommendations for Preoperative Noninvasive Evalua-
tion of Left Ventricular Function
Class I
Patients with current or poorly controlled HF. (If
previous evaluation has documented severe left ventric-
ular dysfunction, repeat preoperative testing may not
be necessary).
Class IIa
Patients with prior HF and patients with dyspnea of
unknown origin.
Class III
As a routine test of left ventricular function in patients
without prior HF.
B. 12-Lead ECG
The resting 12-lead ECG does not identify increased periop-
erative risk in patients undergoing low-risk surgery, but
certain ECG abnormalities are clinical predictors of increased
perioperative and long-term cardiovascular risk in clinically
intermediate- and high-risk patients.41–45
Recommendations for Preoperative 12-Lead Rest ECG
Class I
Recent episode of chest pain or ischemic equivalent in
clinically intermediate- or high-risk patients scheduled
for an intermediate- or high-risk operative procedure.
Class IIa
Asymptomatic persons with diabetes mellitus.
TABLE 3. Cardiac Risk* Stratification for Noncardiac
Surgical Procedures
High (Reported cardiac risk often greater than 5%)
• Emergent major operations, particularly in the elderly
• Aortic and other major vascular surgery
• Peripheral vascular surgery
• Anticipated prolonged surgical procedures associated with large fluid
shifts and/or blood loss
Intermediate (Reported cardiac risk generally less than 5%)
• Carotid endarterectomy
• Head and neck surgery
• Intraperitoneal and intrathoracic surgery
• Orthopedic surgery
• Prostate surgery
Low (Reported cardiac risk generally less than 1%)
• Endoscopic procedures
• Superficial procedure
• Cataract surgery
• Breast surgery
*Combined incidence of cardiac death and nonfatal myocardial infarction.
†Do not generally require further preoperative cardiac testing.
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Class IIb
1. Patients with prior coronary revascularization.
2. Asymptomatic male more than 45 years old or
female more than 55 years old with 2 or more
atherosclerotic risk factors.
3. Prior hospital admission for cardiac causes.
Class III
As a routine test in asymptomatic subjects undergoing
low-risk operative procedures.
C. Exercise or Pharmacological Stress Testing
Recommendations for Exercise or Pharmacological
Stress Testing
Class I
1. Diagnosis of adult patients with intermediate pretest
probability of CAD.
2. Prognostic assessment of patients undergoing initial
evaluation for suspected or proven CAD; evaluation
of subjects with significant change in clinical status.
3. Demonstration of proof of myocardial ischemia be-
fore coronary revascularization.
4. Evaluation of adequacy of medical therapy; prog-
nostic assessment after an acute coronary syndrome
(if recent evaluation unavailable).
Class IIa
Evaluation of exercise capacity when subjective assess-
ment is unreliable.
Class IIb
1. Diagnosis of CAD patients with high or low pretest
probability: those with resting ST depression less
than 1 mm, those taking digitalis therapy, or those
with ECG criteria for left ventricular hypertrophy.
2. Detection of restenosis in high-risk asymptomatic
subjects within the initial months after percutaneous
coronary intervention (PCI).
Class III
1. For exercise stress testing, diagnosis of patients with
resting ECG abnormalities that preclude adequate
assessment, e.g., pre-excitation syndrome, electroni-
cally paced ventricular rhythm, rest ST depression
greater than 1 mm, or left bundle-branch block.
2. Severe comorbidity likely to limit life expectancy or
candidacy for revascularization.
3. Routine screening of asymptomatic men or women.
4. Investigation of isolated ectopic beats in young pa-
tients.
D. Coronary Angiography
Recommendations for Coronary Angiography in Periop-
erative Evaluation Before (or After) Noncardiac Surgery
Class I: Patients With Suspected or Known CAD
1. Evidence for high risk of adverse outcome based on
noninvasive test results.
2. Angina unresponsive to adequate medical therapy.
3. Unstable angina, particularly when facing
intermediate-risk* or high-risk* noncardiac surgery.
4. Equivocal noninvasive test results in patients at high
clinical risk† undergoing high-risk* surgery.
Class IIa
1. Multiple markers of intermediate clinical risk† and
planned vascular surgery (noninvasive testing
should be considered first).
2. Moderate to large ischemia on noninvasive testing but
without high-risk features and lower left ventricular
ejection fraction.
3. Nondiagnostic noninvasive test results in patients at
intermediate clinical risk† undergoing high-risk*
noncardiac surgery.
4. Urgent noncardiac surgery while convalescing from
acute MI.
Class IIb
1. Perioperative MI.
2. Medically stabilized class III or IV angina and
planned low-risk or minor surgery.
Class III
1. Low Risk* noncardiac surgery with known CAD
and no high-risk results on noninvasive testing.
2. Asymptomatic after coronary revascularization with
excellent exercise capacity (greater than or equal to
7 METs).
3. Mild stable angina with good left ventricular func-
tion and no high-risk noninvasive test results.
4. Noncandidate for coronary revascularization owing
to concomitant medical illness, severe left ventricu-
lar dysfunction (e.g., left ventricular ejection frac-
tion less than 0.20), or refusal to consider revascu-
larization.
5. Candidate for liver, lung, or renal transplant less
than 40 years old, as part of evaluation for trans-
plantation, unless noninvasive testing reveals high
risk for adverse outcome.
V. Perioperative Therapy or Previous
Coronary Revascularization
A. Coronary Artery Bypass Grafting
Indications for coronary artery bypass grafting (CABG)
before noncardiac surgery are identical to those reviewed in
the ACC/AHA guidelines for CABG.46 CABG is rarely
indicated simply to “get a patient through” noncardiac sur-
gery. In patients enrolled in the Coronary Artery Surgery
Study (CASS) database, the cardiac risk associated with
noncardiac operations involving the thorax, abdomen, arterial
vasculature, and head and neck was reduced significantly in
those patients who had undergone prior CABG.23 Patients
*Cardiac risk according to type of noncardiac surgery. High risk:
emergent major operations, aortic and major vascular, peripheral vascu-
lar, anticipated prolonged surgical procedure associated with large fluid
shifts and blood loss; intermediate risk: carotid endarterectomy, major
head and neck, intraperitoneal and intrathoracic, orthopedic, prostate; and
low risk: endoscopic procedures, superficial procedures, cataract, breast.
†Cardiac risk according to clinical predictors of perioperative death,
MI, or heart failure. High clinical risk: unstable angina, recent MI, and
evidence of important residual ischemic risk, decompensated heart
failure, high degree of atrioventricular block, symptomatic ventricular
arrhythmias with known structural heart disease, severe symptomatic
valvular heart disease, patient with multiple intermediate risk markers
such as prior MI, heart failure, and diabetes; intermediate clinical risk:
CCS class I or II angina, prior MI by history or ECG, compensated or
prior heart failure, diabetes mellitus and renal insufficiency.
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undergoing elective noncardiac procedures who are found to
have prognostic high-risk coronary anatomy and in whom
long-term outcome would likely be improved by CABG47
should generally undergo revascularization before a noncar-
diac elective surgical procedure of high or intermediate risk
(Table 3).
B. Percutaneous Coronary Intervention
There are no controlled trials comparing perioperative cardiac
outcome after noncardiac surgery for patients treated with
preoperative PCI versus medical therapy. Several small
observational series have suggested that cardiac death is
infrequent in patients who have undergone PCI before non-
cardiac surgery.48–52 Several studies have also demonstrated a
number of complications from angioplasty, including emer-
gency CABG in some patients. Until further data are avail-
able, indications for PCI in the perioperative setting are
similar to those in the ACC/AHA guidelines for use of PCI in
general.53 There is uncertainty regarding how much time
should pass between PCI and noncardiac procedures. Delay-
ing surgery for at least 1 week after balloon angioplasty to
allow for healing of the vessel injury has theoretical benefits. If
a coronary stent is used, a delay of at least 2 weeks and ideally
4 to 6 weeks should occur before noncardiac surgery to allow 4
full weeks of dual antiplatelet therapy and re-endothelialization
of the stent to be completed, or nearly so.54
VI. Perioperative Medical Therapy
Several recent trials have examined the impact of medical
therapy begun just before surgery on reducing cardiac events.
Two randomized, placebo-controlled trials of beta-blocker
administration have been performed.13,14,55,56 One trial demon-
strated reduced perioperative cardiac events, and the other
demonstrated improved 6-month survival with perioperative
beta-blocker usage. Several trials have evaluated the utility of
alpha-2 agonists, demonstrating reduced cardiac event rates
in the subset of patients with known CAD undergoing
vascular surgery.57–60
There are still very few randomized trials of medical
therapy before noncardiac surgery to prevent perioperative
cardiac complications, and they do not provide enough data
from which to draw firm conclusions or recommendations.
Most are insufficiently powered to address the effect on
outcome of MI or cardiac death, and they rely on the
surrogate end point of ECG ischemia to show effect. Current
studies, however, suggest that appropriately administered
beta-blockers reduce perioperative ischemia and may reduce
the risk of MI and death in high-risk patients. When possible,
beta-blockers should be started days or weeks before elective
surgery, with the dose titrated to achieve a resting heart rate
between 50 and 60 beats per minute. Perioperative treatment
with alpha-2 agonists may have similar effects on myocardial
ischemia, infarction, and cardiac death. Clearly, this is an area
in which further research would be valuable.
Recommendations for Perioperative Medical Therapy
Class I
1. Beta-blockers required in the recent past to control
symptoms of angina or patients with symptomatic
arrhythmias or hypertension.
2. Beta-blockers: patients at high cardiac risk owing to
the finding of ischemia on preoperative testing who
are undergoing vascular surgery.
Class IIa
l. Beta-blockers: preoperative assessment identifies un-
treated hypertension, known coronary disease, or
major risk factors for coronary disease.
Class IIb
1. Alpha-2 agonist: perioperative control of hyperten-
sion, or known CAD or major risk factors for CAD.
Class III
1. Beta-blockers: contraindication to beta-blockade.
2. Alpha-2 agonists: contraindication to alpha-2
agonists.
VII. Anesthetic Considerations and
Intraoperative Management
A. Anesthetic Agent
All anesthetic techniques and drugs have known cardiac
effects that should be considered in the perioperative plan.
There appears to be no one best myocardium-protective
anesthetic technique.61–65 Therefore, the choice of anesthesia
and intraoperative monitors is best left to the discretion of the
anesthesia care team, which will consider the need for
postoperative ventilation, cardiovascular effects (including
myocardial depression), sympathetic blockade, and dermato-
mal level of the procedure. Advocates of monitored anesthe-
sia, in which local anesthesia is supplemented by intravenous
sedation/analgesia, have argued that use of this technique
avoids the undesirable effects of general or neuraxial tech-
niques, but no studies have established this. Failure to
produce complete local anesthesia/analgesia can lead to
increased stress response and/or myocardial ischemia.
B. Perioperative Pain Management
Patient-controlled intravenous and/or epidural analgesia is a
popular method for reducing postoperative pain. Several
studies suggest that effective pain management leads to a
reduction in postoperative catecholamine surges and hyper-
coagulability.66,67
C. Intraoperative Nitroglycerin
There are insufficient data about the effects of prophylactic
intraoperative intravenous nitroglycerin in patients at high
risk.68–71 Nitroglycerin should be used only when the hemo-
dynamic effects of other agents in use have been considered.
D. Transesophageal Echocardiography
There are few data on the value of transesophageal echocardi-
ography to detect transient wall motion abnormalities in predict-
ing cardiac morbidity in noncardiac surgical patients.72,73 Expe-
rience to date suggests that the incremental value of this
technique for risk prediction is small.72 Guidelines for appropri-
ate use of transesophageal echocardiography have been pub-
lished by the American Society of Anesthesiologists and the
Society of Cardiovascular Anesthesiologists.74
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E. Perioperative Maintenance of
Body Temperature
One randomized trial demonstrated a reduced incidence of
perioperative cardiac events in patients who were maintained
in a state of normothermia via forced-air warming compared
with routine care.75
VIII. Perioperative Surveillance
A. Pulmonary Artery Catheters
Although very few studies that have been reported compare
patient outcomes after treatment with or without pulmonary
artery catheters, 3 variables are particularly important in
assessing benefit versus risk of pulmonary artery catheter use:
disease severity, magnitude of anticipated surgery, and prac-
tice setting.76 The extent of expected fluid shifts is a primary
concern. Patients most likely to benefit from perioperative
use of a pulmonary artery catheter appear to be those with a
recent MI complicated by HF, those with significant CAD
who are undergoing procedures associated with significant
hemodynamic stress, and those with systolic or diastolic left
ventricular dysfunction, cardiomyopathy, and/or valvular dis-
ease who are undergoing high-risk operations.
B. Intraoperative and Postoperative
ST-Segment Monitoring
Intraoperative and postoperative ST changes indicating myo-
cardial ischemia are strong predictors of perioperative MI in
patients at high risk who undergo noncardiac surgery.77–80
Similarly, postoperative ischemia is a significant predictor of
long-term risk of MI and cardiac death.81 Conversely, in
patients at low risk who undergo noncardiac surgery, ST
depression may occur and often is not associated with
regional wall-motion abnormalities.82–84 Accumulating evi-
dence suggests that proper use of computerized ST-segment
analysis in appropriately selected patients at high risk may
improve sensitivity for myocardial ischemia detection.
C. Surveillance for Perioperative MI
Few studies have examined the optimal method for diagnos-
ing a perioperative MI. Clinical symptoms, postoperative
ECG changes, and elevation of the MB fraction of creatine
kinase (CK-MB) have been studied most extensively. Re-
cently, elevations of myocardium-specific enzymes such as
troponin-I, troponin-T, or CK-MB isoforms have also been
shown to be of value.85–90 In patients with known or suspected
CAD who are undergoing high-risk procedures, ECGs ob-
tained at baseline, immediately after surgery, and on the first
2 days after surgery appear to be cost-effective.91 A risk
gradient can be based on the magnitude of biomarker eleva-
tion, the presence or absence of concomitant new ECG
abnormalities, hemodynamic instability, and quality and in-
tensity of chest pain syndrome, if present. Use of cardiac
biomarkers is best reserved for patients at high risk and those
with clinical, ECG, or hemodynamic evidence of cardiovas-
cular dysfunction.
IX. Postoperative and
Long-Term Management
Despite even optimal perioperative management, some pa-
tients will have perioperative MI, which is associated with a
40% to 70% mortality rate.92 For patients who experience a
symptomatic perioperative ST-segment–elevation MI as a
result of sudden thrombotic coronary occlusion, angioplasty
should be considered after the risks versus benefits have been
weighed. Pharmacological therapy with aspirin should be
initiated as soon as possible, and a beta-blocker and angio-
tensin converting enzyme inhibitor may also be beneficial.
Perioperative MI carries a high risk for future cardiac events.
Patients who sustain acute MI in the perioperative period
should receive careful medical evaluation for residual isch-
emia and overall left ventricular function.
It is also appropriate to recommend secondary risk reduc-
tion in the relatively large number of elective surgery patients
in whom cardiovascular abnormalities are detected during
preoperative evaluations. Although the occasion of surgery is
often taken as a specific high-risk time, most of the patients
who have known or newly detected CAD during their
preoperative evaluations will not have any events during
elective noncardiac surgery. After the preoperative cardiac
risk has been determined by clinical or noninvasive testing,
most patients will benefit from pharmacological agents to
lower low-density lipoprotein cholesterol levels, increase
high-density lipoprotein levels, or both. On the basis of expert
opinion, the goal should be to lower the low-density lipopro-
tein level to less than 100 mg per deciliter (2.6 mmol per
deciliter).93–95
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